Managed Healthcare Executive October 10, 2024
The IQVIA analysis finds that the impact of drug price negotiation on patients’ out-of-pocket spending could also be smaller than expected.
The impact of the Inflation Reduction Act’s drug price negotiations is likely to be more complex, and patients may not see the expected higher out-of-pocket savings, according to a new analysis from IQVIA Institute for Human Data Science that was commissioned by We Work For Health, a life-sciences focused policy organization.
Price negotiations are unlikely to lead to additional savings for patients because the 10 drugs chosen by the Centers for Medicare and Medicaid Services are already subject to aggressive negotiations and significant rebates, the report finds.
IQVIA suggests the out-of-pocket savings for beneficiaries from the IRA’s $2,000 cap...
Today's Sponsors
Today's Sponsor